O
OncoAssign develops AI-powered diagnostic tools utilizing RNA analysis for cancer assessment. These precision diagnostics aim to accurately characterize tumor heterogeneity to guide personalized treatment selection. The company focuses on bringing advanced, personalized oncology diagnostics into clinical practice.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- OncoAssign develops AI-powered diagnostic tools utilizing RNA analysis to improve cancer treatment selection. The platform focuses on addressing tumor heterogeneity to enable truly personalized oncology. This technology aims to ensure patients receive the correct therapy immediately, optimizing treatment efficacy.